High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm

Lala M. Dunbar, Richard G. Wunderink, Michael P Habib, Leon G. Smith, Alan M. Tennenberg, Mohammed M. Khashab, Barbara A. Wiesinger, Jim X. Xiang, Neringa Zadeikis, James B. Kahn

Research output: Contribution to journalArticle

276 Citations (Scopus)

Abstract

Levofloxacin demonstrates concentration-dependent bactericidal activity most closely related to the pharmacodynamic parameters of the ratio of area under the concentration-time curve (AUC) to minimum inhibitory concentration (MIC) and the ratio of peak plasma concentration (Cmax) to MIC. Increasing the dose of levofloxacin to 750 mg exploits these parameters by increasing peak drug concentrations, allowing for a shorter course of treatment without diminishing therapeutic benefit. This was demonstrated in a multicenter, randomized, double-blind investigation that compared levofloxacin dosages of 750 mg per day for 5 days with 500 mg per day for 10 days for the treatment of mild to severe community-acquired pneumonia (CAP). In the clinically evaluable population, the clinical success rates were 92.4% (183 of 198 persons) for the 750-mg group and 91.1% (175 of 192 persons) for the 500-mg group (95% confidence interval, -7.0 to 4.4). Microbiologic eradication rates were 93.2% and 92.4% in the 750-mg and 500-mg groups, respectively. These data demonstrate that 750 mg of levofloxacin per day for 5 days is at least as effective as 500 mg per day for 10 days for treatment of mild-to-severe CAP.

Original languageEnglish (US)
Pages (from-to)752-760
Number of pages9
JournalClinical Infectious Diseases
Volume37
Issue number6
DOIs
StatePublished - Sep 15 2003

Fingerprint

Levofloxacin
Pneumonia
Microbial Sensitivity Tests
Confidence Intervals
Pharmaceutical Preparations
Population
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

Dunbar, L. M., Wunderink, R. G., Habib, M. P., Smith, L. G., Tennenberg, A. M., Khashab, M. M., ... Kahn, J. B. (2003). High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm. Clinical Infectious Diseases, 37(6), 752-760. https://doi.org/10.1086/377539

High-dose, short-course levofloxacin for community-acquired pneumonia : A new treatment paradigm. / Dunbar, Lala M.; Wunderink, Richard G.; Habib, Michael P; Smith, Leon G.; Tennenberg, Alan M.; Khashab, Mohammed M.; Wiesinger, Barbara A.; Xiang, Jim X.; Zadeikis, Neringa; Kahn, James B.

In: Clinical Infectious Diseases, Vol. 37, No. 6, 15.09.2003, p. 752-760.

Research output: Contribution to journalArticle

Dunbar, LM, Wunderink, RG, Habib, MP, Smith, LG, Tennenberg, AM, Khashab, MM, Wiesinger, BA, Xiang, JX, Zadeikis, N & Kahn, JB 2003, 'High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm', Clinical Infectious Diseases, vol. 37, no. 6, pp. 752-760. https://doi.org/10.1086/377539
Dunbar, Lala M. ; Wunderink, Richard G. ; Habib, Michael P ; Smith, Leon G. ; Tennenberg, Alan M. ; Khashab, Mohammed M. ; Wiesinger, Barbara A. ; Xiang, Jim X. ; Zadeikis, Neringa ; Kahn, James B. / High-dose, short-course levofloxacin for community-acquired pneumonia : A new treatment paradigm. In: Clinical Infectious Diseases. 2003 ; Vol. 37, No. 6. pp. 752-760.
@article{b12b61d9aabb46e4a60085ccdbf943a5,
title = "High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm",
abstract = "Levofloxacin demonstrates concentration-dependent bactericidal activity most closely related to the pharmacodynamic parameters of the ratio of area under the concentration-time curve (AUC) to minimum inhibitory concentration (MIC) and the ratio of peak plasma concentration (Cmax) to MIC. Increasing the dose of levofloxacin to 750 mg exploits these parameters by increasing peak drug concentrations, allowing for a shorter course of treatment without diminishing therapeutic benefit. This was demonstrated in a multicenter, randomized, double-blind investigation that compared levofloxacin dosages of 750 mg per day for 5 days with 500 mg per day for 10 days for the treatment of mild to severe community-acquired pneumonia (CAP). In the clinically evaluable population, the clinical success rates were 92.4{\%} (183 of 198 persons) for the 750-mg group and 91.1{\%} (175 of 192 persons) for the 500-mg group (95{\%} confidence interval, -7.0 to 4.4). Microbiologic eradication rates were 93.2{\%} and 92.4{\%} in the 750-mg and 500-mg groups, respectively. These data demonstrate that 750 mg of levofloxacin per day for 5 days is at least as effective as 500 mg per day for 10 days for treatment of mild-to-severe CAP.",
author = "Dunbar, {Lala M.} and Wunderink, {Richard G.} and Habib, {Michael P} and Smith, {Leon G.} and Tennenberg, {Alan M.} and Khashab, {Mohammed M.} and Wiesinger, {Barbara A.} and Xiang, {Jim X.} and Neringa Zadeikis and Kahn, {James B.}",
year = "2003",
month = "9",
day = "15",
doi = "10.1086/377539",
language = "English (US)",
volume = "37",
pages = "752--760",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - High-dose, short-course levofloxacin for community-acquired pneumonia

T2 - A new treatment paradigm

AU - Dunbar, Lala M.

AU - Wunderink, Richard G.

AU - Habib, Michael P

AU - Smith, Leon G.

AU - Tennenberg, Alan M.

AU - Khashab, Mohammed M.

AU - Wiesinger, Barbara A.

AU - Xiang, Jim X.

AU - Zadeikis, Neringa

AU - Kahn, James B.

PY - 2003/9/15

Y1 - 2003/9/15

N2 - Levofloxacin demonstrates concentration-dependent bactericidal activity most closely related to the pharmacodynamic parameters of the ratio of area under the concentration-time curve (AUC) to minimum inhibitory concentration (MIC) and the ratio of peak plasma concentration (Cmax) to MIC. Increasing the dose of levofloxacin to 750 mg exploits these parameters by increasing peak drug concentrations, allowing for a shorter course of treatment without diminishing therapeutic benefit. This was demonstrated in a multicenter, randomized, double-blind investigation that compared levofloxacin dosages of 750 mg per day for 5 days with 500 mg per day for 10 days for the treatment of mild to severe community-acquired pneumonia (CAP). In the clinically evaluable population, the clinical success rates were 92.4% (183 of 198 persons) for the 750-mg group and 91.1% (175 of 192 persons) for the 500-mg group (95% confidence interval, -7.0 to 4.4). Microbiologic eradication rates were 93.2% and 92.4% in the 750-mg and 500-mg groups, respectively. These data demonstrate that 750 mg of levofloxacin per day for 5 days is at least as effective as 500 mg per day for 10 days for treatment of mild-to-severe CAP.

AB - Levofloxacin demonstrates concentration-dependent bactericidal activity most closely related to the pharmacodynamic parameters of the ratio of area under the concentration-time curve (AUC) to minimum inhibitory concentration (MIC) and the ratio of peak plasma concentration (Cmax) to MIC. Increasing the dose of levofloxacin to 750 mg exploits these parameters by increasing peak drug concentrations, allowing for a shorter course of treatment without diminishing therapeutic benefit. This was demonstrated in a multicenter, randomized, double-blind investigation that compared levofloxacin dosages of 750 mg per day for 5 days with 500 mg per day for 10 days for the treatment of mild to severe community-acquired pneumonia (CAP). In the clinically evaluable population, the clinical success rates were 92.4% (183 of 198 persons) for the 750-mg group and 91.1% (175 of 192 persons) for the 500-mg group (95% confidence interval, -7.0 to 4.4). Microbiologic eradication rates were 93.2% and 92.4% in the 750-mg and 500-mg groups, respectively. These data demonstrate that 750 mg of levofloxacin per day for 5 days is at least as effective as 500 mg per day for 10 days for treatment of mild-to-severe CAP.

UR - http://www.scopus.com/inward/record.url?scp=0141676184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141676184&partnerID=8YFLogxK

U2 - 10.1086/377539

DO - 10.1086/377539

M3 - Article

C2 - 12955634

AN - SCOPUS:0141676184

VL - 37

SP - 752

EP - 760

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -